دورية أكاديمية
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
| العنوان: | Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist |
|---|---|
| المؤلفون: | Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop |
| المصدر: | JCI Insight, Vol 5, Iss 17 (2020) |
| بيانات النشر: | American Society for Clinical investigation, 2020. |
| سنة النشر: | 2020 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | Therapeutics, Medicine |
| الوصف: | Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist. Therefore, we hypothesized that the integrated potency and signaling properties of tirzepatide provide a unique pharmacological profile tailored for improving broad metabolic control. Here, we establish methodology for calculating occupancy of each receptor for clinically efficacious doses of the drug. This analysis reveals a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor, corroborating an imbalanced mechanism of action. Pharmacologically, signaling studies demonstrate that tirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP-1 receptor to favor cAMP generation over β-arrestin recruitment, coincident with a weaker ability to drive GLP-1 receptor internalization compared with GLP-1. Experiments in primary islets reveal β-arrestin1 limits the insulin response to GLP-1, but not GIP or tirzepatide, suggesting that the biased agonism of tirzepatide enhances insulin secretion. Imbalance toward GIP receptor, combined with distinct signaling properties at the GLP-1 receptor, together may account for the promising efficacy of this investigational agent. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2379-3708 |
| العلاقة: | https://doaj.org/toc/2379-3708Test |
| DOI: | 10.1172/jci.insight.140532 |
| الوصول الحر: | https://doaj.org/article/03002ae150b14972b6d0c404574ecbbdTest |
| رقم الانضمام: | edsdoj.03002ae150b14972b6d0c404574ecbbd |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.03002ae150b14972b6d0c404574ecbbd 922 3 Academic Journal academicJournal 922.447143554688 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.03002ae150b14972b6d0c404574ecbbd&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/03002ae150b14972b6d0c404574ecbbd [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=23793708&ISBN=&volume=5&issue=17&date=20200901&spage=&pages=&title=JCI Insight&atitle=Tirzepatide%20is%20an%20imbalanced%20and%20biased%20dual%20GIP%20and%20GLP-1%20receptor%20agonist&id=DOI:10.1172/jci.insight.140532 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Francis+S%2E+Willard%22">Francis S. Willard</searchLink><br /><searchLink fieldCode="AR" term="%22Jonathan+D%2E+Douros%22">Jonathan D. Douros</searchLink><br /><searchLink fieldCode="AR" term="%22Maria+B%2EN%2E+Gabe%22">Maria B.N. Gabe</searchLink><br /><searchLink fieldCode="AR" term="%22Aaron+D%2E+Showalter%22">Aaron D. Showalter</searchLink><br /><searchLink fieldCode="AR" term="%22David+B%2E+Wainscott%22">David B. Wainscott</searchLink><br /><searchLink fieldCode="AR" term="%22Todd+M%2E+Suter%22">Todd M. Suter</searchLink><br /><searchLink fieldCode="AR" term="%22Megan+E%2E+Capozzi%22">Megan E. Capozzi</searchLink><br /><searchLink fieldCode="AR" term="%22Wijnand+J%2EC%2E+van+der+Velden%22">Wijnand J.C. van der Velden</searchLink><br /><searchLink fieldCode="AR" term="%22Cynthia+Stutsman%22">Cynthia Stutsman</searchLink><br /><searchLink fieldCode="AR" term="%22Guemalli+R%2E+Cardona%22">Guemalli R. Cardona</searchLink><br /><searchLink fieldCode="AR" term="%22Shweta+Urva%22">Shweta Urva</searchLink><br /><searchLink fieldCode="AR" term="%22Paul+J%2E+Emmerson%22">Paul J. Emmerson</searchLink><br /><searchLink fieldCode="AR" term="%22Jens+J%2E+Holst%22">Jens J. Holst</searchLink><br /><searchLink fieldCode="AR" term="%22David+A%2E+D%27Alessio%22">David A. D’Alessio</searchLink><br /><searchLink fieldCode="AR" term="%22Matthew+P%2E+Coghlan%22">Matthew P. Coghlan</searchLink><br /><searchLink fieldCode="AR" term="%22Mette+M%2E+Rosenkilde%22">Mette M. Rosenkilde</searchLink><br /><searchLink fieldCode="AR" term="%22Jonathan+E%2E+Campbell%22">Jonathan E. Campbell</searchLink><br /><searchLink fieldCode="AR" term="%22Kyle+W%2E+Sloop%22">Kyle W. Sloop</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => JCI Insight, Vol 5, Iss 17 (2020) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => American Society for Clinical investigation, 2020. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Medicine ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist. Therefore, we hypothesized that the integrated potency and signaling properties of tirzepatide provide a unique pharmacological profile tailored for improving broad metabolic control. Here, we establish methodology for calculating occupancy of each receptor for clinically efficacious doses of the drug. This analysis reveals a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor, corroborating an imbalanced mechanism of action. Pharmacologically, signaling studies demonstrate that tirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP-1 receptor to favor cAMP generation over β-arrestin recruitment, coincident with a weaker ability to drive GLP-1 receptor internalization compared with GLP-1. Experiments in primary islets reveal β-arrestin1 limits the insulin response to GLP-1, but not GIP or tirzepatide, suggesting that the biased agonism of tirzepatide enhances insulin secretion. Imbalance toward GIP receptor, combined with distinct signaling properties at the GLP-1 receptor, together may account for the promising efficacy of this investigational agent. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2379-3708 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doaj.org/toc/2379-3708 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1172/jci.insight.140532 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/03002ae150b14972b6d0c404574ecbbd" linkWindow="_blank">https://doaj.org/article/03002ae150b14972b6d0c404574ecbbd</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.03002ae150b14972b6d0c404574ecbbd ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1172/jci.insight.140532
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Therapeutics
[Type] => general
)
[1] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Francis S. Willard
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jonathan D. Douros
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maria B.N. Gabe
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aaron D. Showalter
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => David B. Wainscott
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Todd M. Suter
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Megan E. Capozzi
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wijnand J.C. van der Velden
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cynthia Stutsman
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Guemalli R. Cardona
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shweta Urva
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paul J. Emmerson
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jens J. Holst
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => David A. D’Alessio
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Matthew P. Coghlan
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mette M. Rosenkilde
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jonathan E. Campbell
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kyle W. Sloop
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 09
[Type] => published
[Y] => 2020
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 23793708
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 5
)
[1] => Array
(
[Type] => issue
[Value] => 17
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => JCI Insight
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |